Novel mechanisms of abdominal aortic aneurysms

Current Atherosclerosis Reports

Volumn 14, Issue 5, 2012, Pages 402-412

  Lu, Hong ^a   Rateri, Debra L ^a   Bruemmer, Dennis ^a,b   Cassis, Lisa A ^b   Daugherty, Alan ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Abdominal aortic aneurysms; Cytokines; Macrophages; Phospholipids; Proteases

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN II; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; COMPLEMENT COMPONENT C3; CYCLOSPORIN A; CYSTATIN C; CYSTEINE PROTEINASE; CYTOKINE; DOXYCYCLINE; ELASTASE; INFLIXIMAB; L SELECTIN; LEUKOTRIENE C4; LP 105; MATRIX METALLOPROTEINASE; MICRORNA; MYELOID DIFFERENTIATION FACTOR 88; OSTEOPONTIN; PHOSPHOLIPASE A2; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN E2; QUIFLAPON; ROSIGLITAZONE; SERINE PROTEINASE; SYNDECAN 1; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE;

ABDOMINAL AORTA ANEURYSM; ANTIINFLAMMATORY ACTIVITY; AORTA RUPTURE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY CELL; MOLECULAR MECHANICS; NONHUMAN; REVIEW; SEX DIFFERENCE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; CYTOKINES; HUMANS; MACROPHAGES; PEPTIDE HYDROLASES; TREATMENT OUTCOME;

EID: 84870508249     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0271-y     Document Type: Review

References (122)

1. Pande RL, Beckman JA. Abdominal aortic aneurysm: populations at risk and how to screen. J Vasc Interv Radiol. 2008;19:S2-8.
2. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm. Pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26:2605-13.
3. Lederle FA, Johnson GR, Wilson SE. Abdominal aortic aneurysm in women. J Vasc Surg. 2001;34:122-6.
4. Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis. 2011;217:57-63.
5. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-151.
6. Norman PE, Powell JT. Abdominal aortic aneurysm: the prognosis in women is worse than in men. Circulation. 2007;115:2865-9.
7. Powell JT, Greenhalgh RM. Small abdominal aortic aneurysms. N Engl J Med. 2003;348:1895-901.
8. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation. 2008;118:2382-92.
9. Powell JT, Brady AR. Detection, management, and prospects for the medical treatment of small abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:241-5.
10. Wissler RW, Strong JP. Risk factors and progression of atherosclerosis in youth. PDAY Research Group. Pathological Determinants of Atherosclerosis in Youth. Am J Pathol. 1998;153:1023-33.
11. Anidjar S, Salzmann JL, Gentric D, et al. Elastase-induced experimental aneurysms in rats. Circulation. 1990;82:973-81.
12. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:429-34.
13. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein Edeficient mice. J Clin Invest. 2000;105:1605-12.
14. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-9.
15. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002;110:625-32.
16. Daugherty A, Cassis L. Angiotensin II and abdominal aortic aneurysms. Curr Hypertens Rep. 2004;6:442-6.
17. Lu H, Rateri DL, Cassis LA, Daugherty A. The role of the reninangiotensin system in aortic aneurysmal diseases. Curr Hypertens Rep. 2008;10:99-106.
18. Daugherty A, Cassis LA, Lu H. Complex pathologies of angiotensin II-induced abdominal aortic aneurysms. J Zhejiang Univ Sci B. 2011;12:624-8.
19. Lu H, Rateri DL, Bruemmer D et al.: Involvement of the reninangiotensin system in abdominal and throacic aortic aneurysms. Clin Sci. 2012;123:531-543.
20. Freestone T, Turner RJ, Higman DJ, et al. Influence of hypercholesterolemia and adventitial inflammation on the development of aortic aneurysm in rabbits. Arterioscler Thromb Vasc Biol. 1997;17:10-7.
21. Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1621-6.
22. Police SB, Thatcher SE, Charnigo R, et al. Obesity promotes inflammation in periaortic adipose tissue and angiotensin IIinduced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2009;29:1458-64.
23. Police SB, Putnam K, Thatcher S, et al. Weight loss in obese C57BL/6 mice limits adventitial expansion of established angiotensin II-induced abdominal aortic aneurysms. Am J Physiol Heart Circ Physiol. 2010;298:H1932-8.
24. Rateri DL, Howatt DA, Moorleghen JJ, et al. Prolonged infusion of angiotensin II in apoE-/- mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysms. Am J Pathol. 2011;179:1542-8.
25. Daugherty A, Rateri DL, Charo IF, et al. Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond). 2010;118:681-9.
26. Ishibashi M, Egashira K, Zhao Q, et al. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2004;24:174-8.
27. MacTaggart JN, Xiong W, Knispel R, Baxter BT. Deletion of CCR2 but not CCR5 or CXCR3 inhibits aortic aneurysm formation. Surgery. 2007;142:284-8.
28. Owens 3rd AP, Rateri DL, Howatt DA, et al. MyD88 deficiency attenuates angiotensin II-induced abdominal aortic aneurysm formation independent of signaling through toll-like receptors 2 and 4. Arterioscler Thromb Vasc Biol. 2011;31:2813-9.
29. Findeisen HM, Gizard F, Zhao Y, et al. Telomerase deficiency in bone marrow-derived cells attenuates angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2011;31:253-60.
30. Yin M, Zhang J, Wang Y, et al. Deficient CD4+CD25+ T regulatory cell function in patients with abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2010;30:1825-31.
31. Shimizu K, Shichiri M, Libby P, et al. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest. 2004;114:300-8.
32. Uchida HA, Kristo F, Rateri DL, et al. Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice. Atherosclerosis. 2010;211:399-403.
33. Cohen JR, Keegan L, Sarfati I, et al. Neutrophil chemotaxis and neutrophil elastase in the aortic wall in patients with abdominal aortic aneurysms. J Invest Surg. 1991;4:423-30.
34. Eliason JL, Hannawa KK, Ailawadi G, et al. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation. 2005;112:232-40.
35. Hannawa KK, Eliason JL, Woodrum DT, et al. L-selectinmediated neutrophil recruitment in experimental rodent aneurysm formation. Circulation. 2005;112:241-7.
36. Tsuruda T, Kato J, Hatakeyama K, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res. 2008;102:1368-77.
37. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007;117:3359-68.
38. Swedenborg J, Mayranpaa MI, Kovanen PT. Mast cells: important players in the orchestrated pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2011;31:734-40.
39. Middleton RK, Lloyd GM, Bown MJ, et al. The proinflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg. 2007;45:574-80.
40. Juvonen J, Surcel HM, Satta J, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1997;17:2843-7.
41. Golledge AL, Walker P, Norman PE, Golledge J. A systematic review of studies examining inflammation associated cytokines in human abdominal aortic aneurysm samples. Dis Markers. 2009;26:181-8.
42. Satoh H, Nakamura M, Satoh M, et al. Expression and localization of tumour necrosis factor-alpha and its converting enzyme in human abdominal aortic aneurysm. Clin Sci (Lond). 2004;106:301-6.
43. Kaneko H, Anzai T, Horiuchi K, et al. Tumor necrosis factoralpha converting enzyme is a key mediator of abdominal aortic aneurysm development. Athero. 2011;218:470-8.
44. Koole D, Hurks R, Schoneveld A et al.: Osteoprotegerin is associated with aneurysm diameter and proteolysis in abdominal aortic aneurysm disease. Arterioscler Thromb Vasc Biol. 2012;32:1497-1504.
45. Xiong W, MacTaggart J, Knispel R, et al. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol. 2009;183:2741-6.
46. Xanthoulea S, Thelen M, Pottgens C, et al. Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient mice. PLoS One. 2009;4:e6113.
47. Golledge J, Clancy P, Jones GT, et al. Possible association between genetic polymorphisms in transforming growth factor beta receptors, serum transforming growth factor beta1 concentration and abdominal aortic aneurysm. Br J Surg. 2009;96:628-32.
48. Biros E, Walker PJ, Nataatmadja M, et al. Downregulation of transforming growth factor, beta receptor 2 and Notch signaling pathway in human abdominal aortic aneurysm. Atherosclerosis. 2012;221:383-6.
49. Wang Y, Ait-Oufella H, Herbin O, et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-32.
50. Dai J, Losy F, Guinault AM, et al. Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy. Circulation. 2005;112:1008-15.
51. Dai J, Michineau S, Franck G, et al. Long term stabilization of expanding aortic aneurysms by a short course of cyclosporine A through transforming growth factor-beta induction. PLoS One. 2011;6:28903.
52. Lindeman JH, Rabelink TJ, van Bockel JH. Immunosuppression and the abdominal aortic aneurysm: doctor jekyll or mister hyde? Circulation. 2011;124:e463-5.
53. Pagano MB, Zhou HF, Ennis TL, et al. Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm. Circulation. 2009;119:1805-13.
54. Zhou HF, Yan H, Stover CM, et al. Antibody directs properdindependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proc Natl Acad Sci USA. 2012;109:415-22.
55. Wu G, Chen T, Shahsafaei A, et al. Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice. Circulation. 2010;121:1338-46.
56. Takagi H, Manabe H, Kawai N, et al. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis. Interact Cardiovasc Thorac Surg. 2009;9:437-40.
57. Petrinec D, Liao S, Holmes DR, et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996;23:336-46.
58. Curci JA, Petrinec D, Liao S, et al. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg. 1998;28:1082-93.
59. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483-8.
60. Turner GH, Olzinski AR, Bernard RE, et al. In vivo serial assessment of aortic aneurysm formation in apolipoprotein Edeficient mice via MRI. Circ Cardiovasc Imaging. 2008;1:220-6.
61. Xiong W, Knispel R, MacTaggart J, et al. Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo. J Biol Chem. 2009;284:1765-71.
62. Longo GM, Buda SJ, Fiotta N, et al. MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery. 2005;137:457-62.
63. Pagano MB, Bartoli MA, Ennis TL, et al. Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc Natl Acad Sci USA. 2007;104:2855-60.
64. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-94.
65. Shi GP, Sukhova GK, Grubb A, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999;104:1191-7.
66. Sun J, Sukhova GK, Zhang J, et al. Cathepsin L activity is essential to elastase perfusion-induced abdominal aortic aneurysms in mice. Arterio thromb Vasc Biol. 2011;31:2500-8.
67. Sun J, Sukhova GK, Zhang J, et al. Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol. 2012;32:15-23.
68. Bai L, Beckers L, Wijnands E, et al. Cathepsin K gene disruption does not affect murine aneurysm formation. Atherosclerosis. 2009;209:96-103.
69. Schulte S, Sun J, Libby P, et al. Cystatin C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice. Am J Pathol. 2010;177:456-63.
70. Subramanian V, Uchida HA, Ijaz T, et al. Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. J Cardiovasc Pharmacol. 2012;59:66-76.
71. Sun J, Zhang J, Lindholt JS, et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation. 2009;120:973-82.
72. Inoue N, Muramatsu M, Jin D, et al. Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II-infused apoE-deficient mice. J Atheroscler Thromb. 2009;16:164-71.
73. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest. 2008;118:3012-24.
74. Qian HS, Gu JM, Liu P, et al. Overexpression of PAI-1 prevents the development of abdominal aortic aneurysm in mice. Gene Ther. 2008;15:224-32.
75. Deng GG, Martin-McNulty B, Sukovich DA, et al. Urokinasetype plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res. 2003;92:510-7.
76. Uchida HA, Poduri A, Subramanian V, et al. Urokinase-type plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms. Arterio Thromb Vasc Biol. 2011;31:2845-52.
77. Di Gennaro A, Wagsater D, Mayranpaa MI, et al. Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm. Proc Natl Acad Sci USA. 2010;107:21093-7.
78. Zhao L, Moos MP, Grabner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004;10:966-73.
79. Cao RY, Adams MA, Habenicht AJ, Funk CD. Angiotensin IIinduced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice. Prostag Other Lipid Mediat. 2007;84:34-42.
80. Revermann M, Mieth A, Popescu L, et al. A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine aortic aneurysm model. Br J Pharmacol. 2011;163:1721-32.
81. Holmes DR, Wester W, Thompson RW, Reilly JM. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg. 1997;25:810-5.
82. Miralles M, Wester W, Sicard GA, et al. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the Cox2 isoform of cyclooxygenase. J Vasc Surg. 1999;29:884-93.
83. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res. 2007;73:227-36.
84. King VL, Trivedi D, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysmformation inmice. Arterioscler Thromb Vasc Biol. 2006;26:1137-43.
85. Wang M, Lee E, Song W, et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation. 2008;117:1302-9.
86. Bayston T, Ramessur S, Reise J, et al. Prostaglandin E-2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Surg. 2003;38:354-9.
87. Yokoyama U, Ishiwata R, Jin MH, et al. Inhibition of EP4 Signaling Attenuates Aortic Aneurysm Formation. PLoS One. 2012;7:e36724.
88. Tang EH, Shvartz E, Shimizu K, et al. Deletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin IIinduced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2011;31:261-9.
89. Zack M, Boyanovsky BB, Shridas P, et al. Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. Atherosclerosis. 2011;214:58-64.
90. Watanabe K, Fujioka D, Saito Y, et al. Group X secretory PLA2 in neutrophils plays a pathogenic role in abdominal aortic aneurysms in mice. Am J Physiol Heart Circ Physiol. 2012;302:H95-104.
91. Bruemmer D, Collins AR, Noh G, et al. Angiotensin IIaccelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003;112:1318-31.
92. Schultz G, Tedesco MM, Sho E, et al. Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice. Arterioscler Thromb Vasc Biol. 2010;30:1363-70.
93. Xiao J, Angsana J, Wen J, et al. Syndecan-1 displays a protective role in aortic aneurysm formation by modulating T cell-mediated responses. Arterioscler Thromb Vasc Biol. 2012;32:386-96.
94. Ramos-Mozo P, Madrigal-Matute J, Martinez-Pinna R, et al. Proteomic analysis of polymorphonuclear neutrophils identifies catalase as a novel biomarker of abdominal aortic aneurysm: potential implication of oxidative stress in abdominal aortic aneurysm progression. Arterioscler Thromb Vasc Biol. 2011;31:3011-9.
95. Xiong W, Mactaggart J, Knispel R, et al. Inhibition of reactive oxygen species attenuates aneurysm formation in a murine model. Atherosclerosis. 2009;202:128-34.
96. Gavrila D, Li WG, McCormick ML, et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1671-7.
97. Moran CS, Cullen B, Campbell JH, Golledge J. Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. J Vasc Res. 2008;46:209-17.
98. Golledge J, Cullen B, Rush C, et al. Peroxisome proliferatoractivated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis. 2010;210:51-6.
99. Jones A, Deb R, Torsney E, et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation. 2009;119:3125-32.
100. Hamblin M, Chang L, Zhang H, et al. Vascular smooth muscle cell peroxisome proliferator-activated receptor-gamma deletion promotes abdominal aortic aneurysms. J Vasc Surg. 2010;52:984-93.
101. Subramanian V, Golledge J, Ijaz T, et al. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPARgamma. Circ Res. 2010;107:953-8.
102. Takagi H, Matsui M, Umemoto T. A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J Vasc Surg. 2010;52:1675-81.
103. Shiraya S, Miyake T, Aoki M, et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis. 2008;202:34-40.
104. Kalyanasundaram A, Elmore JR, Manazer JR, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg. 2006;43:117-24.
105. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005;241:92-101.
106. Zhang Y, Naggar JC, Welzig CM, et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol. 2009;29:1764-71.
107. Golledge J, Cullen B, Moran C, Rush C. Efficacy of simvastatin in reducing aortic dilatation in mouse models of abdominal aortic aneurysm. Cardiovasc Drugs Ther. 2010;24:373-8.
108. Wang JA, Chen WA, Wang Y, et al. Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms. Atherosclerosis. 2011;217:90-6.
109. Maegdefessel L, Azuma J, Toh R, et al. Inhibition of microRNA-29b reducesmurine abdominal aortic aneurysm development. J Clin Invest. 2012;122:497-506.
110. Boon RA, Seeger T, Heydt S, et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res. 2011;109:1115-9.
111. Milewicz DM. MicroRNAs, fibrotic remodeling, and aortic aneurysms. J Clin Invest. 2012;122:490-3.
112. Maegdefessel L, Azuma J, Toh R, et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med. 2012;4:122ra22.
113. Ailawadi G, Eliason JL, Roelofs KJ, et al. Gender differences in experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2004;24:2116-22.
114. Sinha I, Cho BS, Roelofs KJ, et al. Female gender attenuates cytokine and chemokine expression and leukocyte recruitment in experimental rodent abdominal aortic aneurysms. Ann NY Acad Sci. 2006;1085:367-79.
115. Manning MW, Cassis LA, Huang J, et al. Abdominal aortic aneurysms: fresh insights from a novel animal model of the disease. Vasc Med. 2002;7:45-54.
116. Henriques TA, Huang J, D'Souza SS, et al. Orchidectomy, but not ovariectomy, regulates angiotensin II-induced vascular diseases in apolipoprotein E-deficient mice. Endocrinology. 2004;145:3866-72.
117. Henriques T, Zhang X, Yiannikouris FB, et al. Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28:1251-6.
118. Martin McNulty B, Tham DM, daCunha V, et al. 17 beta-estradiol attenuates development of angiotensin II induced aortic abdominal aneurysm in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1627-32.
119. Zhang X, Thatcher SE, Rateri DL et al.: Transient exposure of neonatal female mice to testosterone abrogates the sexual dimorphism of abdominal aortic aneurysms. Circ Res. 2012;110:e73-85.
120. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005;11:1330-8.
121. Barisione C, Charnigo R, Howatt DA, et al. Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography. J Vasc Surg. 2006;44:372-6.
122. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann NY Acad Sci. 1999;878:159-78.